基本信息
浏览量:484
职业迁徙
个人简介
Dr. Kirkwood received his medical degree in 1973 from Yale University and completed postgraduate work at Yale-New Haven Hospital and then Harvard University and Dana-Farber Cancer Center. After forming the Yale Melanoma Unit he joined the University of Pittsburgh Cancer Institute in 1986 as Founding Associate Director and Chief of Medical Oncology, and the Director of the Melanoma Center. He has been Professor of Medicine, Dermatology, and Translational Science at the University of Pittsburgh, and the Senior Investigator for the University in ECOG, as well as Chairman of the Melanoma Committee of ECOG-ACRIN. He is also the Chairman of the International Melanoma Working Group founded with the Aim at Melanoma foundation in 2006. He has been the Principal Investigator of the Specialized Program of Research Excellence in Melanoma and Skin Cancer since 2008.
Dr. Kirkwood’s research has focused on melanoma, a cancer that afflicts 60,000 and kills more than 8,000 in the United States each year. Under Dr. Kirkwood’s direction, the Melanoma Center has developed new and effective treatment approaches for this disease. He has received international acclaim for leading a multicenter study developed on the basis of his pioneering work with immunomodulators for melanoma that provided the first FDA-approved adjuvant therapy of melanoma in 1996. He has led more than 160 trials over the past 25 years evaluating cytotoxic, molecular, and immunomodulator therapies including vaccines for metastatic and high-risk melanoma. His research has focused upon the analysis of the molecular and immunologic basis of melanoma progression, in studies that have focused upon advanced and adjuvant disease therapy, using novel designs including the first neoadjuvant applications of IFN and ipilimumab. He has developed prognostic and predictive biomarkers that may allow us to refine application of existing and novel therapies.
Dr. Kirkwood has is leading a number of highly promising clinical trials with cancer vaccines, using biological response modifiers, to spur the body’s own immune system to recognize and destroy melanoma. Since his appointment as Director of the Melanoma Center, he has been pursuing translational investigations of immunotherapies and molecularly targeted agents, alone and in combination with one another. Phase I-II and III studies of cytokines, IFNs, antibodies and vaccines have systematically evaluated therapeutic mechanisms and the induction of antitumor and autoimmunity and the use of neoadjuvant trial designs has identified the importance of STAT signaling and immune cell infiltrates as markers of IFN and anti-CTLA4 blocking antibody efficacy, to accelerate progress from phase I-II into phase III national and international studies, and to refine and optimize application of available agents on the basis of these translational studies in human melanoma
Dr. Kirkwood conducts laboratory research on the molecular and biological changes in atypical nevi, as non-obligate precursors and risk markers of melanoma. These studies seek to providing means for earlier detection and prevention of this cancer.
研究兴趣
论文共 832 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Ankit Mangla, Chanmi Lee, Matthew M Mirsky, Margaret Wang,Luke D Rothermel, Richard Hoehn,Jeremy S Bordeaux, Bryan T Carrol, Jason Theuner,Shawn Li,Pingfu Fu,John M Kirkwood
JAMA oncology (2024)
crossref(2024)
Future oncology (London, England) (2024)
Nature Medicineno. 3 (2024): 906-906
IMMUNOTHERAPYno. 1 (2024): 29-42
Nature Medicineno. 2 (2024): 607-607
Journal of clinical oncology : official journal of the American Society of Clinical Oncologypp.JCO2302355-JCO2302355, (2024)
Dirk Schadendorf,Jason John Luke,Paolo A Ascierto,Georgina V Long,Piotr Rutkowski, Adnan Khattak,Michele Del Vecchio,Luis de la Cruz-Merino,Jacek Mackiewicz, Vanna Chiarion Sileni,John M Kirkwood,Caroline Robert,
Journal for immunotherapy of cancerno. 3 (2024)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn